ADMA Biologics Inc (NASDAQ:ADMA) Stock Has Consensus Target Price of $18.67 According to Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has received a consensus rating of “Moderate Buy” from the six analysts that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $18.67.

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of ADMA Biologics in a research report on Monday, September 14th. Zacks Research raised shares of ADMA Biologics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, September 2nd. Finally, Mizuho lowered their price objective on shares of ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th.

ADMA Biologics Stock Performance

Shares of ADMA opened at $10.36 on Monday. ADMA Biologics has a 12 month low of $7.21 and a 12 month high of $20.46. The firm has a fifty day simple moving average of $9.59 and a 200 day simple moving average of $9.24. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of 14.80 and a beta of 0.70. The company has a current ratio of 6.97, a quick ratio of 3.81 and a debt-to-equity ratio of 0.49.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. ADMA Biologics had a net margin of 32.98% and a return on equity of 40.17%. The business had revenue of $124.39 million during the quarter, compared to the consensus estimate of $125.34 million. During the same period last year, the business posted $0.14 EPS. ADMA Biologics’s revenue was up 2.0% on a year-over-year basis. Research analysts forecast that ADMA Biologics will post 0.78 EPS for the current fiscal year.

Institutional Trading of ADMA Biologics

Several hedge funds and other institutional investors have recently made changes to their positions in ADMA. Western Wealth Management LLC acquired a new stake in ADMA Biologics during the 1st quarter worth about $31,000. Integrated Wealth Concepts LLC acquired a new stake in ADMA Biologics in the second quarter valued at approximately $42,000. Quantbot Technologies LP bought a new stake in ADMA Biologics during the 2nd quarter valued at $51,000. Nykredit A S bought a new position in ADMA Biologics in the 2nd quarter valued at about $59,000. Finally, GAMMA Investing LLC boosted its position in shares of ADMA Biologics by 110.8% during the third quarter. GAMMA Investing LLC now owns 6,119 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 3,216 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a commercial biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for people with compromised immune systems. The company’s operations include collecting human source plasma, developing therapies from donated plasma and producing specialty immunoglobulin products.

ADMA’s commercial portfolio includes BIVIGAM, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency, and ASCENIV, an intravenous immune globulin product for patients with primary immunodeficiency diseases.